Greenwood Capital Associates’s AbbVie ABBV Stock Holding History

Greenwood Capital Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Sell	5,301 -20	-0.4%	-$4.3K	0.13%	137
2026 Q1	$1.16M	Sell	5,321 -59	-1%	-$13.1K	0.13%	142
2025 Q4	$1.23M	Buy	5,380 +341	+7%	+$77.7K	0.13%	131
2025 Q3	$1.17M	Buy	5,039 +492	+11%	+$100K	0.13%	131
2025 Q2	$844K	Buy	+4,547	New	+$845K	0.11%	149
2022 Q2	–	Sell	-708	Closed	-$115K	–	205
2022 Q1	$115K	Sell	708 -13,342	-95%	-$1.94M	0.03%	149
2021 Q4	$1.9M	Buy	14,050 +1,808	+15%	+$214K	0.27%	70
2021 Q3	$1.32M	Buy	12,242 +1,708	+16%	+$195K	0.2%	91
2021 Q2	$1.19M	Buy	10,534 +2,211	+27%	+$249K	0.18%	96
2021 Q1	$901K	Buy	8,323 +2,884	+53%	+$308K	0.14%	119
2020 Q4	$582K	Buy	5,439 +1,791	+49%	+$172K	0.1%	152
2020 Q3	$320K	Buy	+3,648	New	+$343K	0.06%	160
2019 Q3	–	Sell	-42,005	Closed	-$3.06M	–	171
2019 Q2	$3.06M	Buy	+42,005	New	+$3.3M	0.77%	49
2019 Q1	–	Sell	-4,400	Closed	-$406K	–	168
2018 Q4	$406K	Buy	+4,400	New	+$387K	0.11%	111
2015 Q3	–	Sell	-38,569	Closed	-$2.59M	–	152
2015 Q2	$2.59M	Sell	38,569 -5,145	-12%	-$336K	0.78%	53
2015 Q1	$2.56M	Buy	43,714 +494	+1%	+$29.8K	0.73%	64
2014 Q4	$2.83M	Buy	43,220 +371	+0.9%	+$23.4K	0.82%	52
2014 Q3	$2.48M	Buy	+42,849	New	+$2.38M	0.76%	57

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Greenwood Capital Associates's ABBV Position: Q2 2026 in Review

Greenwood Capital Associates reduced its AbbVie (ABBV) stake by 0.38% in Q2 2026, selling an estimated $4.3K and leaving 5,301 shares worth $1.33M. The position accounts for 0.13% of the portfolio, ranked #137.

Greenwood Capital Associates first reported a position in ABBV in Q3 2014 and has held it in 18 quarters since. The position peaked at $3.06M in Q2 2019. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Greenwood Capital Associates held 5,301 shares of AbbVie worth $1.33M as of Q2 2026.
Greenwood Capital Associates sold 20 AbbVie shares in Q2 2026, an estimated $4.3K.
AbbVie made up 0.13% of Greenwood Capital Associates's portfolio in Q2 2026, its #137 holding.
Greenwood Capital Associates first reported a position in AbbVie in Q3 2014 and has held it in 18 quarters since.
Greenwood Capital Associates's AbbVie position peaked at $3.06M in Q2 2019.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.